Learn about free on-demand learning
Reference our medication guides for helpful information
Make a choice that matters
The best care starts with the best information
CERTOLIZUMAB PEGOL (Cimzia) is a recombinant, humanized antibody to a Fab’ fragment, with specificity for human TNF-α; it is conjugated to an approximately 40kDa polyethylene glycol (PEG2MAL40K). The Fab’ fragment is manufactured in E. coli and is subsequently subjected to purification and conjugation to PEG2MAL40K, to generate certolizumab pegol.
FDA-Approved Indications and Dosing
Updated January 2017 - ARHP Practice Committee
DISCLAIMER:The information contained in this biologic reference guide is offered solely for purposes of providing health care professionals with a quick and initial reference. Before prescribing or administering any drug contained in this biologic reference guide, health professionals should read the manufacturer’s complete prescribing information in order to be informed of the various clinical considerations to be taken into account. The American College of Rheumatology is providing this information as a benefit and service in furtherance of its educational mission. By providing this information, ACR is not endorsing or recommending any of the listed companies or any of their drugs or other products. The information contained in the biologic reference guides reflect the conclusions of the individual companies and not those of the ACR which specifically disclaims any responsibility or liability for the use of such information and/or for the performance of any of the drugs listed in this biologic reference guide.
© 2017 American College of Rheumatology